Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(2.04)
# 2,991
Out of 4,914 analysts
115
Total ratings
41.18%
Success rate
-8.64%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Maintains: Buy | $38 → $48 | $31.51 | +52.33% | 6 | Jul 28, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $10 → $12 | $5.06 | +137.15% | 6 | Jul 18, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.20 | +566.67% | 4 | Jun 27, 2025 | |
| ARDX Ardelyx | Assumes: Buy | $10 | $4.28 | +133.64% | 1 | Jun 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $13.60 | +208.82% | 9 | Jun 17, 2025 | |
| LYRA Lyra Therapeutics | Maintains: Neutral | $2 → $16 | $7.80 | +105.13% | 8 | Jun 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $20 | $8.80 | +127.27% | 10 | Jun 9, 2025 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $8 | $3.59 | +122.84% | 1 | Jun 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Assumes: Buy | $72 | $41.75 | +72.46% | 1 | May 27, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $5.32 | +87.97% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $16.45 | +82.37% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.65 | +1,032.08% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $9.31 | +243.72% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.08 | +825.93% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.66 | +1,729.27% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $2.14 | -6.54% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $8.24 | -63.59% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $4.64 | +675.86% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $316.64 | -91.16% | 1 | Aug 22, 2023 |
LENZ Therapeutics
Jul 28, 2025
Maintains: Buy
Price Target: $38 → $48
Current: $31.51
Upside: +52.33%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $5.06
Upside: +137.15%
Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.20
Upside: +566.67%
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $4.28
Upside: +133.64%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $13.60
Upside: +208.82%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2 → $16
Current: $7.80
Upside: +105.13%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $8.80
Upside: +127.27%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.59
Upside: +122.84%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $41.75
Upside: +72.46%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.32
Upside: +87.97%
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $16.45
Upside: +82.37%
May 15, 2025
Reiterates: Buy
Price Target: $30
Current: $2.65
Upside: +1,032.08%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $9.31
Upside: +243.72%
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $1.08
Upside: +825.93%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.66
Upside: +1,729.27%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $2.14
Upside: -6.54%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $8.24
Upside: -63.59%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $4.64
Upside: +675.86%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $316.64
Upside: -91.16%